Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up‐regulation and T cell activation
Open Access
- 7 May 2003
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 33 (6) , 1508-1518
- https://doi.org/10.1002/eji.200323671
Abstract
Active targeting of CpG-containing oligodeoxynucleotide (CpG-ODN) to macrophages was studied by incorporating it in mannose-coated liposomes, using visceral leishmaniasis as the model macrophage disease. Mannosylated liposomal CpG-ODN was more effective than liposomal or free CpG-ODN in inhibiting amastigote multiplication within macrophages. Moreover, in a 60-day mouse model of visceralleishmaniasis, complete elimination of spleen parasite burden was achieved by mannosylated liposomal CpG-ODN, compared to 62% and 81% parasite suppression by free and liposomal ODN, respectively, at a similar dose. Although in vitro exposure of CpG-ODN did not induce marked nitric oxide (NO) generation by macrophages, considerably enhanced amount of NO was generated by macrophages ofCpG-ODN-treated animals. Their splenocytes secreted soluble factors required for the induction of NO generation, and the increased NO generation was paralleled by an increase in antileishmanial activity. Inducible NO generation was suppressed by treating splenocyte supernatants with anti-IFN-γ or anti-IL-12 antibodies, whereas in vivo administration of these anti-cytokine Ab along with CpG-ODN reversed protection against infection. CpG-ODN treatment resulted in reduced levels of IL-4, but increased levels of IFN-γ, IL-12 and inducible NO synthase in infected spleen cells, which was magnified by encapsulation in mannose-coated liposomes. This targeted treatment was not only curative, but it also imparted resistance to reinfection. These results represent a general approach for intracellular targeting of CpG-ODN, which effectively enhances its therapeutic potential in redirecting curative Th1 responses in Th2-driven disorders.Keywords
This publication has 34 references indexed in Scilit:
- The Capacity to Produce IFN-gamma Rather Than the Presence of Interleukin-4 Determines the Resistance and the Degree of Susceptibility to Leishmania donovani Infection in MiceJournal of Interferon & Cytokine Research, 2000
- Role of Endogenous Endonucleases and Tissue Site in Transfection and CpG-Mediated Immune Activation after Naked DNA InjectionHuman Gene Therapy, 1999
- Synergistic Effect of Interferon‐γ and Mannosylated Liposome‐Incorporated Doxorubicin in the Therapy of Experimental Visceral LeishmaniasisThe Journal of Infectious Diseases, 1999
- Requirement for Type 2 NO Synthase for IL-12 Signaling in Innate ImmunityScience, 1999
- Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12Clinical Immunology and Immunopathology, 1997
- Delivery of Cytokines by Liposomes. III. Liposome- Encapsulated GM-CSF and TNF-?? Show Improved Pharmacokinetics and Biological Activity and Reduced Toxicity in MiceJournal of Immunotherapy, 1997
- Engineering liposomes for drug delivery: progress and problemsTrends in Biotechnology, 1995
- Macrophage‐T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania‐infected macrophages and its implication in the suppression of cell‐mediated immunityEuropean Journal of Immunology, 1995
- Recent advances in liposomal drug-delivery systemsCurrent Opinion in Biotechnology, 1995
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993